Drug Approvals Quarterly Update: April 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process....

publications High Cost Therapy Profile: January 2025 Tabelecleucel Intravenous (IV) Oncology January 8, 2025 Proposed indications Epstein-Barr virus-positive (EBV+) post-transplant...

publications High-Cost Therapy Profile: June 2025 Zopapogene imadenovec Subcutaneous (SC) | Precigen, Inc. Infectious Disease June 18, 2025 Proposed indications Recurrent respiratory...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care

research 8 research posters presented by Prime at the 2024 AMCP Annual Meeting Prime remains at the forefront of researching real-world drug utilization, managed care pharmacy programs, and costs...

AMCP Annual Meeting 2025 research posters Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model Click on the poster image to view the full-size version. Prime...

Help lower costs with biosimilars We actively promote evidence-based use of biosimilars to help you make the most of your integrated drug strategy. Breadcrumb Home Our solutions Condition...

publications Weight management: A holistic journey May 1, 2024 Obesity is a global epidemic and major public health issue that has grown in prevalence over recent decades in adults, adolescents...

Expert Clinical Network Insights Hemophilia December 17, 2024 Medication insights: marstacimab-hncq (Hympavzi) The U.S. Food and Drug Administration (FDA) approved marstacimab-hncq (Hympavzi) in...

publications Drug Approvals: July 2024 Monthly update on newly approved specialty and traditional drugs, new indications and first-time generic launches July 31, 2024 Specialty New drugs Jun. 20,...